Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.

Nambu R, Iwama I, Takeuchi I, Hagiwara SI, Etani Y, Kaji E, Yoden A, Kakuta F, Hoshi Y, Tsumura N, Mizuochi T, Kumagai H, Yokoyama K, Nishizawa T, Usami M, Takaki Y, Ebana R, Kurasawa S, Fujikawa H, Ishige T, Kudo T, Yoshida MM, Shimizu H, Arai K

Open source

DOI: 10.1007/s00535-025-02334-9
Published: 2026 Apr
Container: Journal of gastroenterology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00535-025-02334-9,
  title = {Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.},
  author = {Nambu R and Iwama I and Takeuchi I and Hagiwara SI and Etani Y and Kaji E and Yoden A and Kakuta F and Hoshi Y and Tsumura N and Mizuochi T and Kumagai H and Yokoyama K and Nishizawa T and Usami M and Takaki Y and Ebana R and Kurasawa S and Fujikawa H and Ishige T and Kudo T and Yoshida MM and Shimizu H and Arai K},
  year = {2026},
  journal = {Journal of gastroenterology},
  doi = {10.1007/s00535-025-02334-9},
  url = {https://doi.org/10.1007/s00535-025-02334-9}
}

RIS

TY  - JOUR
TI  - Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.
AU  - Nambu R
AU  - Iwama I
AU  - Takeuchi I
AU  - Hagiwara SI
AU  - Etani Y
AU  - Kaji E
AU  - Yoden A
AU  - Kakuta F
AU  - Hoshi Y
AU  - Tsumura N
AU  - Mizuochi T
AU  - Kumagai H
AU  - Yokoyama K
AU  - Nishizawa T
AU  - Usami M
AU  - Takaki Y
AU  - Ebana R
AU  - Kurasawa S
AU  - Fujikawa H
AU  - Ishige T
AU  - Kudo T
AU  - Yoshida MM
AU  - Shimizu H
AU  - Arai K
PY  - 2026
JO  - Journal of gastroenterology
DO  - 10.1007/s00535-025-02334-9
UR  - https://doi.org/10.1007/s00535-025-02334-9
ER  -

APA

R, N., I, I., I, T., SI, H., Y, E., E, K., A, Y., F, K., Y, H., N, T., T, M., H, K., K, Y., T, N., M, U., Y, T., R, E., S, K., H, F., T, I., T, K., MM, Y., H, S., & K, A. (2026). Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.. Journal of gastroenterology. https://doi.org/10.1007/s00535-025-02334-9

Source records

pubmed · retrieved 2026-09-26T20:32:15.581Z
europe-pmc · retrieved 2026-09-26T20:32:15.594Z